KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70270 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Kensuke Takaoka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Iowa Health Care, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: Mutation, Proto-Oncogene Proteins p21(ras), Leukemia, Myeloid, Acute, MAP Kinase Signaling System. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Somatic mutations in the MAPK signaling pathway are frequently identified at AML diagnosis; however, their impact on treatment resistance and long‐term survival remains unclear. We conducted a retrospective study of patients with newly diagnosed MAPK‐mutated AML seen at the University of Iowa Health Care. The endpoints were overall survival (OS), composite complete remission (CRc) following induction therapy, and relapse‐free survival (RFS). Logistic and Cox regression models were used. Seventy‐four patients were included and 62 were induction eligible. Of the 62 patients receiving treatment, intensive induction was administered in 52.7%. The estimated 5‐year OS was 28.9%. On multivariable analysis, European LeukemiaNet 2022 adverse risk (hazard ratio [HR]: 3.56, 95% confident interval [CI]: 1.52–8.32) and KRAS mutation (HR: 2.14, 95% CI: 1.10–4.17) conferred inferior OS. Abnormal karyotype (odds ratio [OR]: 0.25, 95% CI: 0.07–0.89) and increasing age (OR: 0.97, 95% CI: 0.94–0.99) were associated with decreased odds of achieving a CRc. The median RFS after achieving a CRc was 13.3 months. We found that KRAS mutation conferred an inferior effect on OS and RFS but not CRc. These findings suggest that KRAS mutations may confer adverse prognostic significance and warrant validation in larger, multicenter cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Iowa Health Care, Iowa City, Iowa, USA.
- University of Iowa Health Care, Holden Comprehensive Cancer Center, Iowa City, Iowa, USA.
- Department of Medicine, University of Hawai'i John A. Burns School of Medicine, Honolulu, Hawaii, USA.
ORCID-Profile: Kensuke Takaoka, Sakditad Saowapa, Chalothorn Wannaphut, Kittika Poonsombudlert
Zitieren
APA
Takaoka, K., Mott, S., Yodsuwan, R., Saowapa, S., Tanariyakul, M., Wannaphut, C., & Poonsombudlert, K. (2026). KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations. European Journal of Haematology. https://doi.org/10.1111/ejh.70270
Vancouver
Takaoka K, Mott S, Yodsuwan R, Saowapa S, Tanariyakul M, Wannaphut C, et al. KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations. European Journal of Haematology. 2026. doi:10.1111/ejh.70270
BibTeX
@article{Takaoka2026,
author = {Takaoka, Kensuke and Mott, Sarah and Yodsuwan, Ratdanai and Saowapa, Sakditad and Tanariyakul, Manasawee and Wannaphut, Chalothorn and Poonsombudlert, Kittika},
title = {KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70270}
}
EUVIMED